Print page

Background

The European Malaria Vaccine Initiative, EMVI was established in 1998 by the European Commission and interested European Union Member States, in order to address identified structural deficiencies in public funded malaria vaccine development.

The aim of EMVI is to provide a mechanism through which the development of experimental malaria vaccines can be accelerated within Europe and in developing countries.

EMVI shall facilitate and contribute financially and technically to nationally and internationally funded malaria vaccine research and development, and will provide a mechanism to see candidate molecules through to limited industrial production and clinical trials in close collaboration with the African Malaria Network Trust (AMANET).

EMVI will provide a forum for scientists and policy makers engaged in malaria vaccine research and development.

Reference: Hagan P, Bjorvatn B and Jepsen S. European Malaria Vaccine Initiative. Parasitol Today 15: 47-48, 1999

Vision

In the context of the Millennium Development Goals, the European Commission (EC) and several governmental development agencies have committed themselves to reducing the burden of poverty related diseases, including malaria.

In the fight against malaria, vaccines are key assets, and therefore, accelerated development of safe and efficacious vaccines is a top priority.

The vision of the European Malaria Vaccine Initiative (EMVI) is a world free of the intolerable disease burden of malaria within the coming decades.

Mission

The mission of EMVI is to contribute to the global efforts to control malaria by:

  • providing a mechanism for accelerated development and clinical trials of malaria vaccines in Europe and Developing Countries, 
  • promoting affordability and accessibility of malaria vaccines in Developing Countries,  
  • engaging European and international resources committed to malaria vaccine research.

    The specific objective of EMVI is to bridge the conceptual and operational gaps between the bench product - i.e. candidate molecules - and further validation, limited production and clinical testing, thus, making further industrial development and production feasible. EMVI should position itself as the European Malaria Vaccine Development Agency and be recognised as such by all stakeholders.